Cantargia receives capital injection and attracts new board members
Cantargia, a private biopharmaceutical company developing therapeutics for the treatment of leukemia, announces the conclusion of the first step in their financial plan and reinforces the board.As a first step in a long term financial strategy Cantargia has received a capital injection of 3 MSEK from its current main shareholder, LU Bioscience AB (LU Bio). After the financing, LU Bio´s shareholding in Cantargia amounts to 59,2%. Sven Andréasson has been appointed as chairman of the board. Sven Andréasson has extensive experience in both pharmaceutical and biotech companies. He was CEO of